Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2013 Aug 29;8(8):e71784.
doi: 10.1371/journal.pone.0071784. eCollection 2013.

Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis

Usman A Khan  1 , Amit X Garg, Chirag R Parikh, Steven G Coca
Affiliations
Meta-Analysis

Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis

Usman A Khan et al. PLoS One. .

Abstract

Objectives: To perform a systematic review of randomized controlled trials to determine whether prevention or slowing of progression of chronic kidney disease would translate into improved mortality, and if so, the attributable risk due to CKD itself on mortality.

Background: CKD is associated with increased mortality. This association is largely based on evidence from the observational studies and evidence from randomized controlled trials is lacking.

Methods: We searched Ovid, Medline and Embase for RCTs in which an intervention was given to prevent or slow the progression of CKD and mortality was reported as primary, secondary or adverse outcomes were eligible and selected. For the first phase, pooled relative risks for renal endpoints were assessed. For the second phase, we assessed the effect on mortality in trials of interventions that definitively reduced CKD endpoints.

Results: Among 52 studies selected in first phase, only renin-angiotensin-aldosterone-system blockade vs. placebo (n = 18 trials, 32,557 participants) met the efficacy criteria for further analysis in the second phase by reducing renal endpoints 15 to 27% compared to placebo. There was no difference in all-cause mortality (RR 0.99, 95% CI 0.92 to 1.08) or CV death (RR 0.97, 95% CI 0.78 to 1.21) between the treatment and control groups in these trials. There was sufficient statistical power to detect a 9% relative risk reduction in all-cause mortality and a 14% relative risk reduction in cardiovascular mortality.

Conclusions: Firm evidence is lacking that prevention of CKD translates into reductions in mortality. Larger trials with longer follow-up time are needed to determine the benefit of CKD prevention on survival.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Flow Diagram of Study Selection Process.
Figure 2
Figure 2. Pooled Relative Risk for Renal Endpoints in Renin-Angiotensin-Aldosterone-System (RAAS) Trials.
Figure 3
Figure 3. Pooled Relative Risk for Mortality in RAAS Trials.
See this image and copyright information in PMC

References

    1. CDC (2007) Prevalence of chronic kidney disease and associated risk factors–United States, 1999–2004. MMWR Morb Mortal Wkly Rep 56: 161–165. - PubMed
    1. Zhang QL, Rothenbacher D (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8: 117. - PMC - PubMed
    1. NKF (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1–266. - PubMed
    1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305. - PubMed
    1. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, et al. (2001) Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 12: 218–225. - PubMed